Retinitis Pigmentosa Syndrome Clinical Trial
— ECVSOfficial title:
Evaluation of the Visual Field on the Ground: Impact on Locomotion Rehabilitation Adults With Retinitis Pigmentosa With Loss of Peripheral Vision
NCT number | NCT03989622 |
Other study ID # | I15007 |
Secondary ID | |
Status | Not yet recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2019 |
Est. completion date | June 2023 |
Verified date | April 2019 |
Source | University Hospital, Limoges |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Retinopathy pigmentosa (which affects about 40,000 patients in France) leads to destruction
of the peripheral retina. This condition, often familial, frequently affects young patients.
Visual acuity is excellent for a long time, the disease affecting the central macular region
only belatedly. On the other hand, the visual field is very quickly narrowed to a central or
paracentral zone.
For the patient, knowing the limits of his visual field and learning to adapt is necessary
especially when traveling.
The management of these patients is twofold:
- an orthoptist carries out an overall evaluation of the visual field using the Goldmann
device (30 cm projection of the areas seen and not seen by the patient's eye), then
performs rehabilitation over several weeks
- an instructor of locomotion (open specialization: occupational therapist, case of this
project,...) carries out an evaluation in situation, followed by a personalized
reeducation over several weeks. The first sessions consist in establishing a climate of
confidence, presenting the objectives of the management of locomotion and begin to
understand the movements inside and outside accompanied. The following of the
rehabilitation is an apprenticeship of the optimal use of the residual field of vision
and the proposed technical aids (white cane), in the whole of the displacements, inside
and outside.
The residual field of vision is evaluated by a device at the first appointment at the
specialized center. This examination, necessary for the professional, is not informative for
the patient. It is sometimes supplemented by the evaluation of the visual field of view
(ECVS). The ECVS, done jointly by the orthoptist and the locomotion instructor, consists in
evaluating the functional visual field on a horizontal plane at 1m (meter) and 5m, and
vertical at 5m. The field of vision of the patient, immobile, is materialized by targets
deposited at each limit of the zones seen that it indicates.
The investigators believe that the passing of a visual field on the ground, thanks to the
projection of the zones of vision, allows the patient to improve his knowledge on his visual
possibilities (and gaps) and thus to make his reeducation more efficient.
Status | Not yet recruiting |
Enrollment | 52 |
Est. completion date | June 2023 |
Est. primary completion date | October 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - patient at least 18 years old - patient with retinitis pigmentosa - a visual field less than or equal to 20 degrees regardless of the degree of visual acuity - lack of peripheral islets - to be able to move without a white detection cane - have signed an informed consent - be an affiliate or beneficiary of a French social security system. Exclusion Criteria: - severe disorders of transparent media that may interfere with visual impairment related to retinitis pigmentosa - impossibility to follow the protocol - Limitation of locomotion activities related to other than visual impairments: neurological disorders (hemiplegia, neuropathy, ...) - musculoskeletal disorders (arthropathies ...) - Any participation in a protocol having an impact on the walking path by Virtual Reality - person under the protection of justice, or under guardianship or curators - pregnant or lactating woman |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Limoges |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | difference in the number of errors committed during a walk between T0 and T2 | difference in the number of errors committed (= number of hurdles, number of "doors" forgotten) during a walk between T0 (before ECVS) and T2 (after ECVS + 10 re-education sessions). | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05392751 -
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
|
Phase 1/Phase 2 |